PAVmed Management
Management criteria checks 2/4
PAVmed's CEO is Lishan Aklog, appointed in Jun 2014, has a tenure of 9.75 years. total yearly compensation is $1.45M, comprised of 62.1% salary and 37.9% bonuses, including company stock and options. directly owns 4.67% of the company’s shares, worth €950.27K. The average tenure of the management team and the board of directors is 1.5 years and 9.2 years respectively.
Key information
Lishan Aklog
Chief executive officer
US$1.5m
Total compensation
CEO salary percentage | 62.1% |
CEO tenure | 9.8yrs |
CEO ownership | 4.7% |
Management average tenure | 1.5yrs |
Board average tenure | 9.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2023 | n/a | n/a | -US$71m |
Jun 30 2023 | n/a | n/a | -US$79m |
Mar 31 2023 | n/a | n/a | -US$90m |
Dec 31 2022 | US$1m | US$901k | -US$89m |
Sep 30 2022 | n/a | n/a | -US$86m |
Jun 30 2022 | n/a | n/a | -US$72m |
Mar 31 2022 | n/a | n/a | -US$58m |
Dec 31 2021 | US$9m | US$583k | -US$51m |
Sep 30 2021 | n/a | n/a | -US$42m |
Jun 30 2021 | n/a | n/a | -US$35m |
Mar 31 2021 | n/a | n/a | -US$30m |
Dec 31 2020 | US$1m | US$431k | -US$35m |
Sep 30 2020 | n/a | n/a | -US$32m |
Jun 30 2020 | n/a | n/a | -US$30m |
Mar 31 2020 | n/a | n/a | -US$28m |
Dec 31 2019 | US$890k | US$431k | -US$17m |
Sep 30 2019 | n/a | n/a | -US$17m |
Jun 30 2019 | n/a | n/a | -US$17m |
Mar 31 2019 | n/a | n/a | -US$19m |
Dec 31 2018 | US$772k | US$346k | -US$19m |
Sep 30 2018 | n/a | n/a | -US$12m |
Jun 30 2018 | n/a | n/a | -US$14m |
Mar 31 2018 | n/a | n/a | -US$10m |
Dec 31 2017 | US$444k | US$297k | -US$10m |
Compensation vs Market: Lishan's total compensation ($USD1.45M) is above average for companies of similar size in the German market ($USD411.63K).
Compensation vs Earnings: Lishan's compensation has been consistent with company performance over the past year.
CEO
Lishan Aklog (57 yo)
9.8yrs
Tenure
US$1,450,291
Compensation
Dr. Lishan Aklog, M.D., serves as Executive Chairman at Veris Health Inc. since April 2023. He served as Independent Director at ContraFect Corporation since June 14, 2020 until December 04, 2023. Dr. Aklo...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairman & CEO | 9.8yrs | US$1.45m | 4.67% $ 950.3k | |
President | 7yrs | US$1.11m | 0.63% $ 128.5k | |
Executive VP & COO | 2.1yrs | US$1.44m | 0.22% $ 45.3k | |
Executive VP | less than a year | US$593.10k | 0.056% $ 11.5k | |
Senior VP of Molecular Genetics & Chief Scientific Officer | 1.2yrs | no data | no data | |
Vice President of Investor Relations | no data | no data | no data | |
Executive VP | 1.8yrs | no data | 0% $ 0 | |
Senior VP | 1.2yrs | no data | no data | |
Senior VP & Chief Medical Officer | 1.2yrs | no data | no data |
1.5yrs
Average Tenure
57yo
Average Age
Experienced Management: 1P50's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairman & CEO | 9.8yrs | US$1.45m | 4.67% $ 950.3k | |
Independent Director | 9.2yrs | US$182.23k | 0.81% $ 164.4k | |
Member of Medical Advisory Board | 9.3yrs | no data | no data | |
Independent Director | 2.8yrs | US$173.60k | 0.81% $ 164.4k | |
Independent Director | 9.2yrs | US$163.60k | 0.81% $ 164.4k | |
Member of Medical Advisory Board | 9.3yrs | no data | no data | |
Member of Medical Advisory Board | 9.2yrs | no data | no data | |
Member of Medical Advisory Board | 9.2yrs | no data | no data | |
Independent Vice Chairman | 9.4yrs | US$163.60k | 3.91% $ 796.5k | |
Member of Medical Advisory Board | 9.3yrs | no data | no data | |
Independent Director | 2.9yrs | US$183.60k | 0.81% $ 164.4k | |
Member of Medical Advisory Board | 7.3yrs | no data | no data |
9.2yrs
Average Tenure
60.5yo
Average Age
Experienced Board: 1P50's board of directors are considered experienced (9.2 years average tenure).